Showing results (131-140 of 171) with videos related to

Sort By:
Pageof 18
Translational Lung Cancer Research|September 21, 2020
Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectivesSabine Wessels, Thomas Muley, Petros Christopoulos, et al.
Journal for Immunotherapy of Cancer|August 4, 2025
Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: results of the NEOMUN trialMartin E Eichhorn, Benedikt Niedermaier, Pornpimol Charoentong, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2024
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutationsMiriam Blasi, Jonas Kuon, Heike Lüders, et al.
Scientific Data|February 2, 2024
miR-Blood - a small RNA atlas of human blood componentsJulia Jehn, Franziska Trudzinski, Rastislav Horos, et al.
Lung Cancer (Amsterdam, Netherlands)|August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet studyRajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
International Journal of Cancer|September 25, 2024
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcomeMarcel Wiesweg, Claudia Küter, Johannes Schnorbach, et al.
Cancer Immunology, Immunotherapy : CII|June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Cancers|June 21, 2020
Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung CancerMark Kriegsmann, Christian Haag, Cleo-Aron Weis, et al.
JCO Precision Oncology|August 6, 2025
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung CancerJonas Kulhavy, Katja Maurus, Miriam Blasi, et al.
Pageof 18